Shree Ganesh Remedies working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
200.57×239.13×158.77×
91.57×71.59×58.95×
67.15×72.01×52.02×
224.99×238.71×165.70×
1.70×1.77×—
0.55×0.60×0.74×
1.34×1.33×—
0.68×0.78×—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SGRL₹639.75

Shree Ganesh Remedies Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOCMcap ₹822 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Inventory Days (DIO)158.77239.13200.57
Receivable Days (DSO)58.9571.5991.57
Payable Days (DPO)52.0272.0167.15
Cash Conversion Cycle (days)165.70238.71224.99
Working Capital Turnover—1.771.70
Asset Turnover0.740.600.55
Cash Conversion (CFO/Net Income)—1.331.34
CFO/EBITDA—0.780.68
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.